445 related articles for article (PubMed ID: 1364826)
1. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
Tymkewycz PM; Jones RL; Wilson NH; Marr CG
Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
[TBL] [Abstract][Full Text] [Related]
2. EP 171: a high affinity thromboxane A2-mimetic, the actions of which are slowly reversed by receptor blockade.
Jones RL; Wilson NH; Lawrence RA
Br J Pharmacol; 1989 Apr; 96(4):875-87. PubMed ID: 2743082
[TBL] [Abstract][Full Text] [Related]
3. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
4. Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha.
Krauss AH; Woodward DF; Gibson LL; Protzman CE; Williams LS; Burk RM; Gac TS; Roof MB; Abbas F; Marshall K; Senior J
Br J Pharmacol; 1996 Mar; 117(6):1171-80. PubMed ID: 8882612
[TBL] [Abstract][Full Text] [Related]
5. Competitive antagonism at thromboxane receptors in human platelets.
Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological evidence for thromboxane receptor heterogeneity--implications for the eye.
Krauss AH; Woodward DF; Burk RM; Gac TS; Gibson LL; Protzman CE; Abbass F; Marshall K; Senior J
J Ocul Pharmacol Ther; 1997 Aug; 13(4):303-12. PubMed ID: 9261766
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the prostaglandin E2 sensitive (EP)-receptor in the rat isolated trachea.
Lydford SJ; McKechnie K
Br J Pharmacol; 1994 May; 112(1):133-6. PubMed ID: 8032634
[TBL] [Abstract][Full Text] [Related]
9. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species.
Narumiya S; Okuma M; Ushikubi F
Br J Pharmacol; 1986 Jun; 88(2):323-31. PubMed ID: 3730697
[TBL] [Abstract][Full Text] [Related]
10. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
11. Cinnamophilin, a novel thromboxane A2 receptor antagonist, isolated from Cinnamomum philippinense.
Yu SM; Ko FN; Wu TS; Lee JY; Teng CM
Eur J Pharmacol; 1994 Apr; 256(1):85-91. PubMed ID: 8026563
[TBL] [Abstract][Full Text] [Related]
12. A novel inhibitory prostanoid receptor in piglet saphenous vein.
Coleman RA; Grix SP; Head SA; Louttit JB; Mallett A; Sheldrick RL
Prostaglandins; 1994 Feb; 47(2):151-68. PubMed ID: 8016385
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues.
Matthews JS; Jones RL
Br J Pharmacol; 1993 Feb; 108(2):363-9. PubMed ID: 8448586
[TBL] [Abstract][Full Text] [Related]
14. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets.
Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV
J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275
[TBL] [Abstract][Full Text] [Related]
15. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
16. Antagonistic action of AA-2414 on thromboxane A2/prostaglandin endoperoxide receptor in platelets and blood vessels.
Imura Y; Terashita Z; Shibouta Y; Inada Y; Nishikawa K
Jpn J Pharmacol; 1990 Jan; 52(1):35-43. PubMed ID: 2137886
[TBL] [Abstract][Full Text] [Related]
17. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation.
Furci L; Fitzgerald DJ; Fitzgerald GA
J Pharmacol Exp Ther; 1991 Jul; 258(1):74-81. PubMed ID: 1830100
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.
Armstrong RA; Humphrey PP; Lumley P
Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]